{"pii": "S2211124723015693", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2211124723015693-fx1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2211124723015693/fx1/DOWNSAMPLED/image/jpeg/5f5eaeee99d1b2035cbc517675b1d5bc/fx1.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "37679"}, {"#name": "pixel-height", "_": "375"}, {"#name": "pixel-width", "_": "375"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2211124723015693-fx1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2211124723015693/fx1/THUMBNAIL/image/gif/705fec82b10e427cee95fddee5fa8288/fx1.sml"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "8116"}, {"#name": "pixel-height", "_": "164"}, {"#name": "pixel-width", "_": "164"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2211124723015693-fx1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2211124723015693/HIGHRES/image/jpeg/9352eef110256179c144d0181562fe71/fx1_lrg.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "148181"}, {"#name": "pixel-height", "_": "996"}, {"#name": "pixel-width", "_": "996"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Summary"}, {"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "$$": [{"#name": "__text__", "_": "Metabolic reprogramming in pediatric diffuse midline glioma is driven by gene expression changes induced by the hallmark histone mutation H3K27M, which results in aberrantly permissive activation of oncogenic signaling pathways. Previous studies of diffuse midline glioma with altered H3K27 (DMG-H3K27a) have shown that the RAS pathway, specifically through its downstream kinase, extracellular-signal-related kinase 5 (ERK5), is critical for tumor growth. Further downstream effectors of ERK5 and their role in DMG-H3K27a metabolic reprogramming have not been explored. We establish that ERK5 is a critical regulator of cell proliferation and glycolysis in DMG-H3K27a. We demonstrate that ERK5 mediates glycolysis through activation of transcription factor MEF2A, which subsequently modulates expression of glycolytic enzyme PFKFB3. We show that "}, {"#name": "italic", "_": "in\u00a0vitro"}, {"#name": "__text__", "_": " and mouse models of DMG-H3K27a are sensitive to the loss of PFKFB3. Multi-targeted drug therapy against the ERK5-PFKFB3 axis, such as with small-molecule inhibitors, may represent a promising therapeutic approach in patients with pediatric diffuse midline glioma."}]}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0015"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "link", "$": {"xmlns:xlink": true, "locator": "fx1", "type": "simple", "href": "pii:S2211124723015693/fx1", "id": "aep-link-id8"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "author-highlights", "id": "abs0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0020"}, "_": "Highlights"}, {"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "$$": [{"#name": "list", "$": {"id": "ulist0010"}, "$$": [{"#name": "list-item", "$": {"id": "u0010"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0010", "view": "all"}, "_": "ERK5 regulates cell proliferation and glycolysis in DMG-H3K27a"}]}, {"#name": "list-item", "$": {"id": "u0015"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0015", "view": "all"}, "_": "ERK5 mediates glycolysis through PFKFB3 via the MEF2A transcription factor"}]}, {"#name": "list-item", "$": {"id": "u0020"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0020", "view": "all"}, "_": "DMG-H3K27a models are sensitive to PFKFB3 inhibition"}]}, {"#name": "list-item", "$": {"id": "u0025"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0025", "view": "all"}, "_": "Multi-targeted therapy against ERK5-PFKFB3 axis has clinical potential"}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "teaser", "id": "abs0025", "view": "all"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0025", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0025", "view": "all"}, "_": "Diffuse midline glioma (DMG-H3K27a) is an aggressive pediatric tumor with poor prognosis and limited therapeutic options. Casillo et\u00a0al. show that ERK5 modulates expression of glycolytic enzyme PFKFB3 through MEF2A and that DMG-H3K27a is sensitive to PFKFB3 loss. The ERK5-PFKFB3 axis represents a potential therapeutic target for treatment of DMG-H3K27a."}]}]}]}}